Risks and benefits of extended DAPT after stenting

In patients who received coronary drug-eluting stents, continuation of dual antiplatelet therapy beyond 1 year after stent placement, compared with aspirin therapy alone, is associated with

reduced thrombotic risk and major adverse cardiac events. These findings were reported by investigators of the Dual Antiplatelet Therapy (DAPT) study, and were presented at the AHA

Scientific Sessions 2014 in Chicago, IL, USA and published in The New England Journal Of Medicine.

Current guidelines recommend the use of dual antiplatelet therapy for 6–12 months after stenting for the prevention of coronary stent thrombosis. Until now, little evidence has been reported

to support the benefit of dual antiplatelet therapy beyond 1 year. The DAPT study is the first international, multicentre, randomized, placebo-controlled trial sufficiently powered to

determine the risks and benefits of prolonged dual antiplatelet therapy after stent placement.

Anyone you share the following link with will be able to read this content: